Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India

Januvia Generic Sees Strong Competition

Executive Summary

Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.

You may also be interested in...



India And Brazil Sustain Branded Generics Success For Torrent In Q2

Torrent continues its overall growth trajectory in Q2 of its 2023 financial year, but a flagging German market slows the company’s expansion strategy. The board insists improved sales are just around the corner.

Januvia Generics Arrive: Can MSD Defend Its Turf In India?

A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the company respond with price cuts?

No Smoke Without Fire: Unichem Divests Domestic Business To Torrent

Two years after denying sell-off plans, Unichem Laboratories is divesting its branded business in India and Nepal to peer Torrent for around $558m. The deal catapults Torrent to the top league on the domestic market and also sets the tone for potential consolidation in the Indian pharma space at more realistic valuations.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel